ID   PLEC_HUMAN              Reviewed;        4684 AA.
AC   Q15149; Q15148; Q16640; Q6S376; Q6S377; Q6S378; Q6S379; Q6S380;
AC   Q6S381; Q6S382; Q6S383;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 3.
DT   22-JUL-2015, entry version 180.
DE   RecName: Full=Plectin;
DE            Short=PCN;
DE            Short=PLTN;
DE   AltName: Full=Hemidesmosomal protein 1;
DE            Short=HD1;
DE   AltName: Full=Plectin-1;
GN   Name=PLEC; Synonyms=PLEC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=8633055; DOI=10.1073/pnas.93.9.4278;
RA   Liu C.-G., Maercker C., Castanon M.J., Hauptmann R., Wiche G.;
RT   "Human plectin: organization of the gene, sequence analysis, and
RT   chromosome localization (8q24).";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:4278-4283(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 2 AND 3), DISEASE,
RP   AND VARIANT VAL-1321.
RX   PubMed=8698233; DOI=10.1101/gad.10.14.1724;
RA   McLean W.H.I., Pulkkinen L., Smith F.J.D., Rugg E.L., Lane E.B.,
RA   Bullrich F., Burgeson R.E., Amano S., Hudson D.L., Owaribe K.,
RA   McGrath J.A., McMillan J.R., Eady R.A.J., Leigh I.M., Christiano A.M.,
RA   Uitto J.;
RT   "Loss of plectin causes epidermolysis bullosa with muscular dystrophy:
RT   cDNA cloning and genomic organization.";
RL   Genes Dev. 10:1724-1735(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 4; 5; 6; 7; 8 AND 9).
RX   PubMed=14672974; DOI=10.1101/gr.1225204;
RA   Zhang T., Haws P., Wu Q.;
RT   "Multiple variable first exons: a mechanism for cell- and tissue-
RT   specific gene regulation.";
RL   Genome Res. 14:79-89(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [5]
RP   PROTEIN SEQUENCE OF 14-21; 209-227; 237-248; 301-316; 329-336;
RP   350-365; 372-417; 510-517; 588-597; 631-675; 697-706; 714-724;
RP   734-740; 751-764; 857-869; 897-908; 927-934; 1029-1037; 1045-1052;
RP   1076-1088; 1131-1139; 1166-1175; 1187-1210; 1216-1224; 1227-1243;
RP   1251-1266; 1274-1291; 1318-1335; 1338-1344; 1351-1364; 1366-1382;
RP   1411-1438; 1473-1479; 1499-1508; 1554-1563; 1596-1603; 1606-1616;
RP   1628-1638; 1649-1657; 1671-1679; 1699-1709; 1732-1744; 1783-1792;
RP   1825-1833; 1846-1854; 1867-1875; 1888-1908; 1976-1994; 2006-2014;
RP   2048-2055; 2058-2068; 2079-2087; 2098-2108; 2130-2139; 2142-2150;
RP   2172-2182; 2199-2217; 2310-2316; 2319-2329; 2340-2348; 2361-2379;
RP   2402-2409; 2420-2429; 2432-2442; 2462-2473; 2483-2503; 2512-2521;
RP   2565-2575; 2587-2594; 2651-2663; 2685-2693; 2705-2761; 2768-2787;
RP   2795-2821; 2833-2841; 2847-2881; 2885-2903; 2942-2968; 2979-3007;
RP   3028-3039; 3045-3053; 3095-3106; 3109-3127; 3132-3139; 3146-3154;
RP   3175-3183; 3213-3231; 3244-3259; 3270-3285; 3289-3297; 3317-3335;
RP   3356-3368; 3374-3384; 3424-3436; 3447-3469; 3477-3485; 3506-3513;
RP   3519-3540; 3544-3568; 3601-3637; 3648-3661; 3667-3676; 3686-3702;
RP   3739-3749; 3771-3781; 3784-3804; 3839-3878; 3887-3897; 3926-3963;
RP   3969-3999; 4004-4018; 4027-4060; 4084-4091; 4122-4138; 4159-4167;
RP   4179-4205; 4278-4296; 4339-4348; 4354-4360; 4384-4401; 4429-4447;
RP   4467-4475; 4492-4500; 4543-4551; 4590-4627 AND 4668-4684,
RP   PHOSPHORYLATION AT SER-4385, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Ovarian carcinoma;
RA   Bienvenut W.V., Lilla S., von Kriegsheim A., Lempens A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [6]
RP   FUNCTION, INTERACTION WITH COL17A1, AND SUBCELLULAR LOCATION.
RX   PubMed=12482924; DOI=10.1242/jcs.00241;
RA   Koster J., Geerts D., Favre B., Borradori L., Sonnenberg A.;
RT   "Analysis of the interactions between BP180, BP230, plectin and the
RT   integrin alpha6beta4 important for hemidesmosome assembly.";
RL   J. Cell Sci. 116:387-399(2003).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125; SER-149; SER-720;
RP   SER-1435; SER-1721; THR-4030 AND THR-4411, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [9]
RP   INTERACTION WITH TOR1A.
RX   PubMed=18827015; DOI=10.1242/jcs.029454;
RA   Nery F.C., Zeng J., Niland B.P., Hewett J., Farley J., Irimia D.,
RA   Li Y., Wiche G., Sonnenberg A., Breakefield X.O.;
RT   "TorsinA binds the KASH domain of nesprins and participates in linkage
RT   between nuclear envelope and cytoskeleton.";
RL   J. Cell Sci. 121:3476-3486(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using
RT   sequential IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1435, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125; SER-149; SER-720;
RP   SER-4382; SER-4385; SER-4386; SER-4389; SER-4390; SER-4391; SER-4392;
RP   SER-4396; SER-4613; SER-4622; SER-4626 AND SER-4642, PHOSPHORYLATION
RP   [LARGE SCALE ANALYSIS] AT SER-42 (ISOFORMS 2 AND 3), PHOSPHORYLATION
RP   [LARGE SCALE ANALYSIS] AT SER-21 (ISOFORM 4), AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-720; THR-4030 AND
RP   SER-4626, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4386; SER-4389;
RP   SER-4396; SER-4613; SER-4618 AND SER-4626, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-42 (ISOFORMS 2 AND 3), AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3091 AND LYS-3420, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [18]
RP   FUNCTION OF ISOFORM 9, AND INVOLVEMENT IN LGMD2Q.
RX   PubMed=21109228; DOI=10.1016/j.ajhg.2010.10.017;
RA   Gundesli H., Talim B., Korkusuz P., Balci-Hayta B., Cirak S.,
RA   Akarsu N.A., Topaloglu H., Dincer P.;
RT   "Mutation in exon 1f of PLEC, leading to disruption of plectin isoform
RT   1f, causes autosomal-recessive limb-girdle muscular dystrophy.";
RL   Am. J. Hum. Genet. 87:834-841(2010).
RN   [19]
RP   INTERACTION WITH DST.
RX   PubMed=19932097; DOI=10.1016/j.yexcr.2009.11.010;
RA   Steiner-Champliaud M.F., Schneider Y., Favre B., Paulhe F.,
RA   Praetzel-Wunder S., Faulkner G., Konieczny P., Raith M., Wiche G.,
RA   Adebola A., Liem R.K., Langbein L., Sonnenberg A., Fontao L.,
RA   Borradori L.;
RT   "BPAG1 isoform-b: complex distribution pattern in striated and heart
RT   muscle and association with plectin and alpha-actinin.";
RL   Exp. Cell Res. 316:297-313(2010).
RN   [20]
RP   INVOLVEMENT IN MD-EBS AND EBS-PA.
RX   PubMed=20665883; DOI=10.1002/humu.21330;
RA   Natsuga K., Nishie W., Shinkuma S., Arita K., Nakamura H., Ohyama M.,
RA   Osaka H., Kambara T., Hirako Y., Shimizu H.;
RT   "Plectin deficiency leads to both muscular dystrophy and pyloric
RT   atresia in epidermolysis bullosa simplex.";
RL   Hum. Mutat. 31:E1687-E1698(2010).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-113; SER-125; SER-149;
RP   SER-720; SER-1435; SER-1732; THR-4030; SER-4382; SER-4396; SER-4400;
RP   SER-4613; SER-4622 AND SER-4642, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-42 (ISOFORMS 2 AND 3), PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-20 AND SER-21 (ISOFORM 4), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   INTERACTION WITH ANK3.
RX   PubMed=21223964; DOI=10.1016/j.yexcr.2011.01.002;
RA   Maiweilidan Y., Klauza I., Kordeli E.;
RT   "Novel interactions of ankyrins-G at the costameres: the muscle-
RT   specific Obscurin/Titin-Binding-related Domain (OTBD) binds plectin
RT   and filamin C.";
RL   Exp. Cell Res. 317:724-736(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1435, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-720; SER-1047; SER-1435;
RP   SER-2631; SER-2782; SER-2802; THR-2886; SER-3036; THR-3785; THR-4030;
RP   SER-4054; SER-4386; SER-4390; SER-4392; TYR-4393; SER-4396; SER-4400;
RP   SER-4616; SER-4626 AND SER-4675, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 409-640.
RX   PubMed=17397861; DOI=10.1016/j.jmb.2007.02.090;
RA   Sonnenberg A., Rojas A.M., de Pereda J.M.;
RT   "The structure of a tandem pair of spectrin repeats of plectin reveals
RT   a modular organization of the plakin domain.";
RL   J. Mol. Biol. 368:1379-1391(2007).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 159-403.
RX   PubMed=12791251; DOI=10.1016/S0969-2126(03)00090-X;
RA   Garcia-Alvarez B., Bobkov A., Sonnenberg A., de Pereda J.M.;
RT   "Structural and functional analysis of the actin binding domain of
RT   plectin suggests alternative mechanisms for binding to F-actin and
RT   integrin beta4.";
RL   Structure 11:615-625(2003).
RN   [28]
RP   VARIANT MD-EBS 1003-GLN--ALA-1005 DEL.
RX   PubMed=8894687; DOI=10.1093/hmg/5.10.1539;
RA   Pulkkinen L., Smith F.J.D., Shimizu H., Murata S., Yaoita H.,
RA   Hachisuka H., Nishikawa T., McLean W.H.I., Uitto J.;
RT   "Homozygous deletion mutations in the plectin gene (PLEC1) in patients
RT   with epidermolysis bullosa simplex associated with late-onset muscular
RT   dystrophy.";
RL   Hum. Mol. Genet. 5:1539-1546(1996).
RN   [29]
RP   VARIANT MD-EBS LEU-429 INS.
RX   PubMed=11159198; DOI=10.1016/S0002-9440(10)64003-5;
RA   Bauer J.W., Rouan F., Kofler B., Rezniczek G.A., Kornacker I.,
RA   Muss W., Hametner R., Klausegger A., Huber A., Pohla-Gubo G.,
RA   Wiche G., Uitto J., Hintner H.;
RT   "A compound heterozygous one amino-acid insertion/nonsense mutation in
RT   the plectin gene causes epidermolysis bullosa simplex with plectin
RT   deficiency.";
RL   Am. J. Pathol. 158:617-625(2001).
RN   [30]
RP   VARIANT O-EBS TRP-2110.
RX   PubMed=11851880; DOI=10.1046/j.0022-202x.2001.01591.x;
RA   Koss-Harnes D., Hoeyheim B., Anton-Lamprecht I., Gjesti A.,
RA   Joergensen R.S., Jahnsen F.L., Olaisen B., Wiche G.,
RA   Gedde-Dahl T. Jr.;
RT   "A site-specific plectin mutation causes dominant epidermolysis
RT   bullosa simplex Ogna: two identical de novo mutations.";
RL   J. Invest. Dermatol. 118:87-93(2002).
RN   [31]
RP   INVOLVEMENT IN EBS-PA.
RX   PubMed=14675180; DOI=10.1111/j.1523-1747.2003.12639.x;
RA   Charlesworth A., Gagnoux-Palacios L., Bonduelle M., Ortonne J.-P.,
RA   De Raeve L., Meneguzzi G.;
RT   "Identification of a lethal form of epidermolysis bullosa simplex
RT   associated with a homozygous genetic mutation in plectin.";
RL   J. Invest. Dermatol. 121:1344-1348(2003).
CC   -!- FUNCTION: Interlinks intermediate filaments with microtubules and
CC       microfilaments and anchors intermediate filaments to desmosomes or
CC       hemidesmosomes. Could also bind muscle proteins such as actin to
CC       membrane complexes in muscle. May be involved not only in the
CC       filaments network, but also in the regulation of their dynamics.
CC       Structural component of muscle. Isoform 9 plays a major role in
CC       the maintenance of myofibers integrity.
CC       {ECO:0000269|PubMed:12482924, ECO:0000269|PubMed:21109228}.
CC   -!- SUBUNIT: Homodimer or homotetramer. Interacts (via actin-binding
CC       domain) with SYNE3. Interacts (via CH 1 domain) with VIM (via rod
CC       region). Interacts (via N-terminus) with DST isoform 2 (via N-
CC       terminus). Interacts with FER. Interacts with TOR1A. Interacts
CC       with ANK3. {ECO:0000269|PubMed:12482924,
CC       ECO:0000269|PubMed:18827015, ECO:0000269|PubMed:19932097,
CC       ECO:0000269|PubMed:21223964}.
CC   -!- INTERACTION:
CC       P35637:FUS; NbExp=4; IntAct=EBI-297903, EBI-400434;
CC       P16144:ITGB4; NbExp=7; IntAct=EBI-297903, EBI-948678;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:12482924}. Cell junction, hemidesmosome
CC       {ECO:0000269|PubMed:12482924}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=9;
CC       Name=1; Synonyms=Plectin-6;
CC         IsoId=Q15149-1; Sequence=Displayed;
CC       Name=2; Synonyms=Plectin-1, 1c;
CC         IsoId=Q15149-2; Sequence=VSP_005030;
CC         Note=Contains a phosphoserine at position 42.
CC         {ECO:0000269|PubMed:18669648, ECO:0000269|PubMed:19690332,
CC         ECO:0000269|PubMed:20068231};
CC       Name=3;
CC         IsoId=Q15149-3; Sequence=VSP_005030, VSP_005031;
CC         Note=Contains a phosphoserine at position 42.
CC         {ECO:0000269|PubMed:18669648, ECO:0000269|PubMed:19690332,
CC         ECO:0000269|PubMed:20068231};
CC       Name=4; Synonyms=Plectin-11, 1a;
CC         IsoId=Q15149-4; Sequence=VSP_023510;
CC         Note=Contains a phosphotyrosine at position 26 (By similarity).
CC         Contains a phosphoserine at position 21. Contains a
CC         phosphoserine at position 20. {ECO:0000250,
CC         ECO:0000269|PubMed:18669648, ECO:0000269|PubMed:20068231};
CC       Name=5; Synonyms=Plectin-8, 1b;
CC         IsoId=Q15149-5; Sequence=VSP_037103, VSP_037106;
CC       Name=6; Synonyms=Plectin-10, 1g;
CC         IsoId=Q15149-6; Sequence=VSP_037104, VSP_037105;
CC       Name=7; Synonyms=Plectin-7, 1d;
CC         IsoId=Q15149-7; Sequence=VSP_037100, VSP_037109;
CC       Name=8; Synonyms=Plectin-3, 1e;
CC         IsoId=Q15149-8; Sequence=VSP_037101, VSP_037108;
CC       Name=9; Synonyms=Plectin-2, 1f;
CC         IsoId=Q15149-9; Sequence=VSP_037102, VSP_037107;
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest levels in
CC       muscle, heart, placenta and spinal cord.
CC   -!- DOMAIN: The N-terminus interacts with actin, the C-terminus with
CC       vimentin, desmin, GFAP, cytokeratins, lamin B; whereas both the N-
CC       and the C-terminus can bind integrin beta-4.
CC   -!- PTM: Phosphorylated by CDK1; regulates dissociation from
CC       intermediate filaments during mitosis. {ECO:0000250}.
CC   -!- DISEASE: Epidermolysis bullosa simplex with pyloric atresia (EBS-
CC       PA) [MIM:612138]: Autosomal recessive genodermatosis characterized
CC       by severe skin blistering at birth and congenital pyloric atresia.
CC       Death usually occurs in infancy. This disorder is allelic to MD-
CC       EBS. {ECO:0000269|PubMed:14675180, ECO:0000269|PubMed:20665883}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Epidermolysis bullosa simplex, with muscular dystrophy
CC       (MD-EBS) [MIM:226670]: A form of epidermolysis bullosa
CC       characterized by the association of blister formation at the level
CC       of the hemidesmosome with late-onset muscular dystrophy.
CC       {ECO:0000269|PubMed:11159198, ECO:0000269|PubMed:8894687}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Epidermolysis bullosa simplex, Ogna type (O-EBS)
CC       [MIM:131950]: A form of intraepidermal epidermolysis bullosa
CC       characterized by generalized skin bruising, skin fragility with
CC       non-scarring blistering and small hemorrhagic blisters on hands.
CC       At the ultrastructural level, it is differentiated from classical
CC       cases of K-EBS, WC-EBS and DM-EBS, by the occurrence of blisters
CC       originating in basal cells above hemidesmosomes, and abnormal
CC       hemidesmosome intracellular attachment plates.
CC       {ECO:0000269|PubMed:11851880}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Limb-girdle muscular dystrophy 2Q (LGMD2Q) [MIM:613723]:
CC       A form of limb-girdle muscular dystrophy characterized by early
CC       childhood onset of proximal muscle weakness. Limb-girdle muscular
CC       dystrophies are characterized by proximal weakness, weakness of
CC       the hip and shoulder girdles and prominent asymmetrical quadriceps
CC       femoris and biceps brachii atrophy. {ECO:0000269|PubMed:21109228}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry. A 9 bp deletion containing the
CC       initiation codon in exon 1f of PLEC have been found in limb-girdle
CC       muscular dystrophy patients. The mutation results in deficient
CC       expression of isoform 9 and disorganization of the myofibers,
CC       without any effect on the skin.
CC   -!- SIMILARITY: Belongs to the plakin or cytolinker family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 actin-binding domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 CH (calponin-homology) domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00044}.
CC   -!- SIMILARITY: Contains 33 plectin repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 4 spectrin repeats. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Plectin entry;
CC       URL="http://en.wikipedia.org/wiki/Plectin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z54367; CAA91196.1; -; Genomic_DNA.
DR   EMBL; U53204; AAB05427.1; -; mRNA.
DR   EMBL; U63610; AAB05428.1; -; Genomic_DNA.
DR   EMBL; U63609; AAB05428.1; JOINED; Genomic_DNA.
DR   EMBL; X97053; CAA65765.1; -; mRNA.
DR   EMBL; AY480044; AAR95677.1; -; mRNA.
DR   EMBL; AY480045; AAR95678.1; -; mRNA.
DR   EMBL; AY480046; AAR95679.1; -; mRNA.
DR   EMBL; AY480047; AAR95680.1; -; mRNA.
DR   EMBL; AY480048; AAR95681.1; -; mRNA.
DR   EMBL; AY480049; AAR95682.1; -; mRNA.
DR   EMBL; AY480050; AAR95683.1; -; mRNA.
DR   EMBL; AY480051; AAR95684.1; -; mRNA.
DR   EMBL; AC109322; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS43769.1; -. [Q15149-2]
DR   CCDS; CCDS43770.1; -. [Q15149-9]
DR   CCDS; CCDS43771.1; -. [Q15149-8]
DR   CCDS; CCDS43772.1; -. [Q15149-1]
DR   CCDS; CCDS43773.1; -. [Q15149-5]
DR   CCDS; CCDS43774.1; -. [Q15149-6]
DR   CCDS; CCDS43775.1; -. [Q15149-4]
DR   CCDS; CCDS47936.1; -. [Q15149-7]
DR   PIR; C59404; A59404.
DR   PIR; G02520; G02520.
DR   RefSeq; NP_000436.2; NM_000445.4. [Q15149-2]
DR   RefSeq; NP_958780.1; NM_201378.3. [Q15149-9]
DR   RefSeq; NP_958781.1; NM_201379.2. [Q15149-8]
DR   RefSeq; NP_958782.1; NM_201380.3. [Q15149-1]
DR   RefSeq; NP_958783.1; NM_201381.2. [Q15149-7]
DR   RefSeq; NP_958784.1; NM_201382.3. [Q15149-5]
DR   RefSeq; NP_958785.1; NM_201383.2. [Q15149-6]
DR   RefSeq; NP_958786.1; NM_201384.2. [Q15149-4]
DR   UniGene; Hs.434248; -.
DR   PDB; 1MB8; X-ray; 2.15 A; A=175-403.
DR   PDB; 2ODU; X-ray; 2.30 A; A=410-640.
DR   PDB; 2ODV; X-ray; 2.05 A; A=410-640.
DR   PDB; 3F7P; X-ray; 2.75 A; A/B=175-403.
DR   PDB; 3PDY; X-ray; 2.22 A; A/B=653-858.
DR   PDB; 3PE0; X-ray; 2.95 A; A/B=750-1028.
DR   PDB; 4GDO; X-ray; 1.70 A; A/B/C/D/E/F=1492-1530.
DR   PDB; 4Q58; X-ray; 4.00 A; A/B=175-400.
DR   PDB; 4Q59; X-ray; 2.30 A; A/B=175-400.
DR   PDBsum; 1MB8; -.
DR   PDBsum; 2ODU; -.
DR   PDBsum; 2ODV; -.
DR   PDBsum; 3F7P; -.
DR   PDBsum; 3PDY; -.
DR   PDBsum; 3PE0; -.
DR   PDBsum; 4GDO; -.
DR   PDBsum; 4Q58; -.
DR   PDBsum; 4Q59; -.
DR   ProteinModelPortal; Q15149; -.
DR   SMR; Q15149; 5-101, 175-400, 413-630, 653-1025, 2782-3023, 3441-3681, 4021-4260, 4412-4605.
DR   BioGrid; 111355; 62.
DR   IntAct; Q15149; 28.
DR   MINT; MINT-257064; -.
DR   STRING; 9606.ENSP00000323856; -.
DR   BindingDB; Q15149; -.
DR   ChEMBL; CHEMBL1293240; -.
DR   PhosphoSite; Q15149; -.
DR   BioMuta; PLEC; -.
DR   DMDM; 209572726; -.
DR   MaxQB; Q15149; -.
DR   PaxDb; Q15149; -.
DR   PRIDE; Q15149; -.
DR   Ensembl; ENST00000322810; ENSP00000323856; ENSG00000178209.
DR   Ensembl; ENST00000345136; ENSP00000344848; ENSG00000178209. [Q15149-4]
DR   Ensembl; ENST00000354589; ENSP00000346602; ENSG00000178209. [Q15149-5]
DR   Ensembl; ENST00000354958; ENSP00000347044; ENSG00000178209. [Q15149-8]
DR   Ensembl; ENST00000356346; ENSP00000348702; ENSG00000178209. [Q15149-9]
DR   Ensembl; ENST00000357649; ENSP00000350277; ENSG00000178209. [Q15149-6]
DR   Ensembl; ENST00000398774; ENSP00000381756; ENSG00000178209. [Q15149-7]
DR   Ensembl; ENST00000436759; ENSP00000388180; ENSG00000178209. [Q15149-2]
DR   Ensembl; ENST00000527096; ENSP00000434583; ENSG00000178209. [Q15149-3]
DR   GeneID; 5339; -.
DR   KEGG; hsa:5339; -.
DR   UCSC; uc003zab.1; human. [Q15149-4]
DR   UCSC; uc003zac.1; human. [Q15149-6]
DR   UCSC; uc003zad.2; human. [Q15149-5]
DR   UCSC; uc003zae.1; human. [Q15149-7]
DR   UCSC; uc003zaf.1; human. [Q15149-1]
DR   UCSC; uc003zag.1; human. [Q15149-8]
DR   UCSC; uc003zah.2; human. [Q15149-9]
DR   UCSC; uc003zaj.2; human. [Q15149-2]
DR   CTD; 5339; -.
DR   GeneCards; GC08M144989; -.
DR   GeneReviews; PLEC; -.
DR   H-InvDB; HIX0168901; -.
DR   HGNC; HGNC:9069; PLEC.
DR   HPA; CAB003847; -.
DR   HPA; HPA025967; -.
DR   HPA; HPA029906; -.
DR   MIM; 131950; phenotype.
DR   MIM; 226670; phenotype.
DR   MIM; 601282; gene.
DR   MIM; 612138; phenotype.
DR   MIM; 613723; phenotype.
DR   neXtProt; NX_Q15149; -.
DR   Orphanet; 254361; Autosomal recessive limb-girdle muscular dystrophy type 2Q.
DR   Orphanet; 257; Epidermolysis bullosa simplex with muscular dystrophy.
DR   Orphanet; 158684; Epidermolysis bullosa simplex with pyloric atresia.
DR   Orphanet; 79401; Epidermolysis bullosa simplex, Ogna type.
DR   PharmGKB; PA33399; -.
DR   eggNOG; COG5069; -.
DR   GeneTree; ENSGT00760000119163; -.
DR   HOVERGEN; HBG053616; -.
DR   InParanoid; Q15149; -.
DR   KO; K10388; -.
DR   OMA; YLNKDTH; -.
DR   PhylomeDB; Q15149; -.
DR   TreeFam; TF335163; -.
DR   Reactome; REACT_13541; Caspase-mediated cleavage of cytoskeletal proteins.
DR   Reactome; REACT_150180; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; REACT_20537; Type I hemidesmosome assembly.
DR   ChiTaRS; PLEC; human.
DR   EvolutionaryTrace; Q15149; -.
DR   GeneWiki; Plectin; -.
DR   GenomeRNAi; 5339; -.
DR   NextBio; 20680; -.
DR   PRO; PR:Q15149; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; Q15149; -.
DR   CleanEx; HS_PLEC1; -.
DR   ExpressionAtlas; Q15149; baseline and differential.
DR   Genevisible; Q15149; HS.
DR   GO; GO:0005903; C:brush border; IEA:Ensembl.
DR   GO; GO:0043034; C:costamere; TAS:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0030056; C:hemidesmosome; IDA:UniProtKB.
DR   GO; GO:0045111; C:intermediate filament cytoskeleton; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; NAS:ProtInc.
DR   GO; GO:0042383; C:sarcolemma; IDA:UniProtKB.
DR   GO; GO:0016528; C:sarcoplasm; ISS:BHF-UCL.
DR   GO; GO:0030506; F:ankyrin binding; IPI:BHF-UCL.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0008307; F:structural constituent of muscle; IMP:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0034329; P:cell junction assembly; TAS:Reactome.
DR   GO; GO:0006921; P:cellular component disassembly involved in execution phase of apoptosis; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0031581; P:hemidesmosome assembly; IDA:UniProtKB.
DR   GO; GO:0012501; P:programmed cell death; TAS:Reactome.
DR   Gene3D; 1.10.418.10; -; 2.
DR   Gene3D; 3.90.1290.10; -; 7.
DR   InterPro; IPR001589; Actinin_actin-bd_CS.
DR   InterPro; IPR001715; CH-domain.
DR   InterPro; IPR030269; Plectin.
DR   InterPro; IPR001101; Plectin_repeat.
DR   InterPro; IPR005326; S10_plectin_N.
DR   InterPro; IPR018159; Spectrin/alpha-actinin.
DR   PANTHER; PTHR11915:SF247; PTHR11915:SF247; 1.
DR   Pfam; PF00307; CH; 2.
DR   Pfam; PF00681; Plectin; 18.
DR   Pfam; PF03501; S10_plectin; 1.
DR   SMART; SM00033; CH; 2.
DR   SMART; SM00250; PLEC; 32.
DR   SMART; SM00150; SPEC; 7.
DR   SUPFAM; SSF47576; SSF47576; 1.
DR   SUPFAM; SSF75399; SSF75399; 8.
DR   PROSITE; PS00019; ACTININ_1; 1.
DR   PROSITE; PS00020; ACTININ_2; 1.
DR   PROSITE; PS50021; CH; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Actin-binding; Alternative splicing;
KW   Cell junction; Coiled coil; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Disease mutation;
KW   Epidermolysis bullosa; Limb-girdle muscular dystrophy; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat.
FT   CHAIN         1   4684       Plectin.
FT                                /FTId=PRO_0000078135.
FT   DOMAIN      175    400       Actin-binding.
FT   DOMAIN      179    282       CH 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00044}.
FT   DOMAIN      295    397       CH 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00044}.
FT   REPEAT      645    710       Spectrin 1.
FT   REPEAT      740    824       Spectrin 2.
FT   REPEAT      837    930       Spectrin 3.
FT   REPEAT     1315   1415       Spectrin 4.
FT   REPEAT     2826   2863       Plectin 1.
FT   REPEAT     2864   2901       Plectin 2.
FT   REPEAT     2902   2939       Plectin 3.
FT   REPEAT     2940   2977       Plectin 4.
FT   REPEAT     2981   3015       Plectin 5.
FT   REPEAT     3116   3153       Plectin 6.
FT   REPEAT     3154   3191       Plectin 7.
FT   REPEAT     3192   3229       Plectin 8.
FT   REPEAT     3230   3267       Plectin 9.
FT   REPEAT     3268   3305       Plectin 10.
FT   REPEAT     3306   3343       Plectin 11.
FT   REPEAT     3485   3522       Plectin 12.
FT   REPEAT     3523   3560       Plectin 13.
FT   REPEAT     3561   3598       Plectin 14.
FT   REPEAT     3599   3636       Plectin 15.
FT   REPEAT     3640   3674       Plectin 16.
FT   REPEAT     3820   3857       Plectin 17.
FT   REPEAT     3858   3895       Plectin 18.
FT   REPEAT     3896   3933       Plectin 19.
FT   REPEAT     3934   3971       Plectin 20.
FT   REPEAT     3975   4008       Plectin 21.
FT   REPEAT     4063   4100       Plectin 22.
FT   REPEAT     4101   4138       Plectin 23.
FT   REPEAT     4139   4176       Plectin 24.
FT   REPEAT     4177   4214       Plectin 25.
FT   REPEAT     4218   4252       Plectin 26.
FT   REPEAT     4265   4305       Plectin 27.
FT   REPEAT     4319   4356       Plectin 28.
FT   REPEAT     4408   4445       Plectin 29.
FT   REPEAT     4446   4483       Plectin 30.
FT   REPEAT     4484   4521       Plectin 31.
FT   REPEAT     4522   4559       Plectin 32.
FT   REPEAT     4560   4597       Plectin 33.
FT   REGION        1   1470       Globular 1.
FT   REGION     1471   2755       Central fibrous rod domain.
FT   REGION     2756   4684       Globular 2.
FT   REGION     4250   4300       Binding to intermediate filaments.
FT                                {ECO:0000250}.
FT   REGION     4625   4640       4 X 4 AA tandem repeats of G-S-R-X.
FT   COILED     1469   2756       {ECO:0000255}.
FT   MOD_RES     113    113       Phosphothreonine.
FT                                {ECO:0000269|PubMed:20068231}.
FT   MOD_RES     125    125       Phosphoserine.
FT                                {ECO:0000269|PubMed:17081983,
FT                                ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES     149    149       Phosphoserine.
FT                                {ECO:0000269|PubMed:17081983,
FT                                ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES     720    720       Phosphoserine.
FT                                {ECO:0000269|PubMed:17081983,
FT                                ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19369195,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES    1047   1047       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    1435   1435       Phosphoserine.
FT                                {ECO:0000269|PubMed:17081983,
FT                                ECO:0000269|PubMed:18691976,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:21406692,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES    1721   1721       Phosphoserine.
FT                                {ECO:0000269|PubMed:17081983}.
FT   MOD_RES    1725   1725       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9QXS1}.
FT   MOD_RES    1732   1732       Phosphoserine.
FT                                {ECO:0000269|PubMed:20068231}.
FT   MOD_RES    2631   2631       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    2636   2636       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9QXS1}.
FT   MOD_RES    2782   2782       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    2802   2802       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    2886   2886       Phosphothreonine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    3033   3033       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9QXS1}.
FT   MOD_RES    3036   3036       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    3053   3053       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9QXS1}.
FT   MOD_RES    3091   3091       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES    3362   3362       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9QXS1}.
FT   MOD_RES    3420   3420       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES    3785   3785       Phosphothreonine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    4030   4030       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17081983,
FT                                ECO:0000269|PubMed:19369195,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES    4054   4054       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    4382   4382       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES    4384   4384       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P30427}.
FT   MOD_RES    4385   4385       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|Ref.5}.
FT   MOD_RES    4386   4386       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES    4389   4389       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332}.
FT   MOD_RES    4390   4390       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES    4391   4391       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES    4392   4392       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES    4393   4393       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    4396   4396       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES    4400   4400       Phosphoserine.
FT                                {ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES    4411   4411       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17081983}.
FT   MOD_RES    4539   4539       Phosphothreonine; by CDK1. {ECO:0000250}.
FT   MOD_RES    4613   4613       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES    4615   4615       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9QXS1}.
FT   MOD_RES    4616   4616       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    4618   4618       Phosphoserine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   MOD_RES    4622   4622       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES    4626   4626       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19369195,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES    4642   4642       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES    4675   4675       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   VAR_SEQ       1    174       MVAGMLMPRDQLRAIYEVLFREGVMVAKKDRRPRSLHPHVP
FT                                GVTNLQVMRAMASLRARGLVRETFAWCHFYWYLTNEGIAHL
FT                                RQYLHLPPEIVPASLQRVRRPVAMVMPARRTPHVQAVQGPL
FT                                GSPPKRGPLPTEEQRVYRRKELEEVSPETPVVPATTQRTLA
FT                                RPGPEPAPAT -> MSGEDAEVRAVSEDVSNGSSGSPSPGD
FT                                TLPWNLGKTQRSRRSGGGAGSNGSVLDPAERAVIRIA (in
FT                                isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14672974,
FT                                ECO:0000303|PubMed:8698233}.
FT                                /FTId=VSP_005030.
FT   VAR_SEQ       1    174       MVAGMLMPRDQLRAIYEVLFREGVMVAKKDRRPRSLHPHVP
FT                                GVTNLQVMRAMASLRARGLVRETFAWCHFYWYLTNEGIAHL
FT                                RQYLHLPPEIVPASLQRVRRPVAMVMPARRTPHVQAVQGPL
FT                                GSPPKRGPLPTEEQRVYRRKELEEVSPETPVVPATTQRTLA
FT                                RPGPEPAPAT -> MSQHQLRVPQPEGLGRKRTSSEDNLYL
FT                                AVLRASEGKK (in isoform 4).
FT                                {ECO:0000303|PubMed:14672974}.
FT                                /FTId=VSP_023510.
FT   VAR_SEQ       1    169       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:14672974}.
FT                                /FTId=VSP_037100.
FT   VAR_SEQ       1    159       Missing (in isoform 8).
FT                                {ECO:0000303|PubMed:14672974}.
FT                                /FTId=VSP_037101.
FT   VAR_SEQ       1    151       Missing (in isoform 9).
FT                                {ECO:0000303|PubMed:14672974}.
FT                                /FTId=VSP_037102.
FT   VAR_SEQ       1    137       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14672974}.
FT                                /FTId=VSP_037103.
FT   VAR_SEQ       1    133       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:14672974}.
FT                                /FTId=VSP_037104.
FT   VAR_SEQ     134    174       TEEQRVYRRKELEEVSPETPVVPATTQRTLARPGPEPAPAT
FT                                -> MSGAGGAFASPREVLLERPCWLDGGCEPARRGYLYQQL
FT                                CCV (in isoform 6).
FT                                {ECO:0000303|PubMed:14672974}.
FT                                /FTId=VSP_037105.
FT   VAR_SEQ     138    174       RVYRRKELEEVSPETPVVPATTQRTLARPGPEPAPAT ->
FT                                MEPSGSLFPSLVVVGHVVTLAAVWHWRRGRRWAQDEQ (in
FT                                isoform 5).
FT                                {ECO:0000303|PubMed:14672974}.
FT                                /FTId=VSP_037106.
FT   VAR_SEQ     152    174       TPVVPATTQRTLARPGPEPAPAT -> MAGPLPDEQDFIQA
FT                                YEEVREKYK (in isoform 9).
FT                                {ECO:0000303|PubMed:14672974}.
FT                                /FTId=VSP_037107.
FT   VAR_SEQ     160    174       QRTLARPGPEPAPAT -> MDPSRAIQNEISSLK (in
FT                                isoform 8).
FT                                {ECO:0000303|PubMed:14672974}.
FT                                /FTId=VSP_037108.
FT   VAR_SEQ     170    174       PAPAT -> MKIVP (in isoform 7).
FT                                {ECO:0000303|PubMed:14672974}.
FT                                /FTId=VSP_037109.
FT   VAR_SEQ     409    412       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:8698233}.
FT                                /FTId=VSP_005031.
FT   VARIANT     429    429       L -> LL (in MD-EBS).
FT                                {ECO:0000269|PubMed:11159198}.
FT                                /FTId=VAR_011336.
FT   VARIANT     641    641       A -> V (in dbSNP:rs11136336).
FT                                /FTId=VAR_053585.
FT   VARIANT    1003   1005       Missing (in MD-EBS).
FT                                {ECO:0000269|PubMed:8894687}.
FT                                /FTId=VAR_011337.
FT   VARIANT    1321   1321       L -> V (in dbSNP:rs3135109).
FT                                {ECO:0000269|PubMed:8698233}.
FT                                /FTId=VAR_060088.
FT   VARIANT    1386   1386       R -> Q (in dbSNP:rs11136334).
FT                                /FTId=VAR_060089.
FT   VARIANT    1459   1459       H -> R (in dbSNP:rs55895668).
FT                                /FTId=VAR_062133.
FT   VARIANT    2110   2110       R -> W (in O-EBS).
FT                                {ECO:0000269|PubMed:11851880}.
FT                                /FTId=VAR_015817.
FT   VARIANT    2150   2150       R -> W (in dbSNP:rs34893635).
FT                                /FTId=VAR_053586.
FT   VARIANT    2194   2194       A -> V (in dbSNP:rs7002002).
FT                                /FTId=VAR_053587.
FT   VARIANT    2791   2791       S -> P (in dbSNP:rs7833924).
FT                                /FTId=VAR_053588.
FT   VARIANT    2821   2821       R -> W (in dbSNP:rs35723243).
FT                                /FTId=VAR_053589.
FT   VARIANT    2969   2969       R -> H (in dbSNP:rs6558407).
FT                                /FTId=VAR_053590.
FT   VARIANT    3162   3162       V -> I (in dbSNP:rs35027700).
FT                                /FTId=VAR_053591.
FT   VARIANT    3171   3171       A -> V (in dbSNP:rs35858667).
FT                                /FTId=VAR_053592.
FT   VARIANT    3486   3486       T -> M (in dbSNP:rs34725742).
FT                                /FTId=VAR_053593.
FT   VARIANT    3490   3490       G -> A (in dbSNP:rs35261863).
FT                                /FTId=VAR_053594.
FT   CONFLICT     71     71       Y -> F (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT     94     94       P -> A (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT    139    139       V -> L (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT    185    185       F -> S (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT    259    259       N -> D (in Ref. 2; AAB05427/AAB05428).
FT                                {ECO:0000305}.
FT   CONFLICT    550    550       N -> H (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT    560    560       V -> I (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT    706    706       R -> Q (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT    886    886       Y -> N (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   1002   1002       A -> V (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   1309   1309       V -> L (in Ref. 2; AAB05427/AAB05428).
FT                                {ECO:0000305}.
FT   CONFLICT   1334   1334       V -> L (in Ref. 2; AAB05427/AAB05428).
FT                                {ECO:0000305}.
FT   CONFLICT   1534   1534       M -> I (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   1662   1662       A -> T (in Ref. 2; AAB05427/AAB05428).
FT                                {ECO:0000305}.
FT   CONFLICT   1688   1690       RLR -> WLC (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   1767   1767       E -> Q (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   1789   1789       A -> L (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   1910   1910       R -> K (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   2154   2154       K -> N (in Ref. 2; AAB05427/AAB05428/
FT                                CAA65765 and 3; AAR95680/AAR95682/
FT                                AAR95683). {ECO:0000305}.
FT   CONFLICT   2160   2160       R -> S (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   2215   2215       Q -> R (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   2244   2244       S -> A (in Ref. 1; CAA91196 and 2;
FT                                AAB05427/AAB05428/CAA65765).
FT                                {ECO:0000305}.
FT   CONFLICT   3027   3027       K -> E (in Ref. 2; AAB05427/AAB05428).
FT                                {ECO:0000305}.
FT   CONFLICT   3310   3310       A -> E (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3361   3361       L -> F (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3408   3408       L -> F (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3447   3447       A -> S (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3531   3531       A -> G (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3580   3580       S -> R (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3589   3589       Q -> K (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3596   3596       Q -> E (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3616   3616       H -> N (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3686   3686       A -> V (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3786   3786       A -> G (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3808   3808       R -> K (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3816   3816       A -> G (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3821   3821       C -> F (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3915   3915       Q -> K (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   3999   3999       R -> K (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   4007   4007       T -> S (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   CONFLICT   4467   4467       F -> L (in Ref. 1; CAA91196).
FT                                {ECO:0000305}.
FT   HELIX       175    193       {ECO:0000244|PDB:1MB8}.
FT   HELIX       194    196       {ECO:0000244|PDB:4Q59}.
FT   TURN        203    209       {ECO:0000244|PDB:1MB8}.
FT   HELIX       211    221       {ECO:0000244|PDB:1MB8}.
FT   HELIX       233    249       {ECO:0000244|PDB:1MB8}.
FT   HELIX       260    263       {ECO:0000244|PDB:1MB8}.
FT   HELIX       267    282       {ECO:0000244|PDB:1MB8}.
FT   TURN        283    285       {ECO:0000244|PDB:4Q59}.
FT   HELIX       297    308       {ECO:0000244|PDB:1MB8}.
FT   TURN        309    311       {ECO:0000244|PDB:1MB8}.
FT   HELIX       322    324       {ECO:0000244|PDB:1MB8}.
FT   HELIX       328    337       {ECO:0000244|PDB:1MB8}.
FT   HELIX       339    341       {ECO:0000244|PDB:1MB8}.
FT   HELIX       344    347       {ECO:0000244|PDB:1MB8}.
FT   HELIX       352    367       {ECO:0000244|PDB:1MB8}.
FT   HELIX       375    378       {ECO:0000244|PDB:1MB8}.
FT   STRAND      380    382       {ECO:0000244|PDB:1MB8}.
FT   HELIX       385    398       {ECO:0000244|PDB:1MB8}.
FT   HELIX       414    440       {ECO:0000244|PDB:2ODV}.
FT   HELIX       448    464       {ECO:0000244|PDB:2ODV}.
FT   HELIX       466    488       {ECO:0000244|PDB:2ODV}.
FT   STRAND      490    492       {ECO:0000244|PDB:2ODU}.
FT   HELIX       500    562       {ECO:0000244|PDB:2ODV}.
FT   TURN        563    566       {ECO:0000244|PDB:2ODV}.
FT   HELIX       572    598       {ECO:0000244|PDB:2ODV}.
FT   HELIX       604    628       {ECO:0000244|PDB:2ODV}.
FT   HELIX       656    678       {ECO:0000244|PDB:3PDY}.
FT   HELIX       685    714       {ECO:0000244|PDB:3PDY}.
FT   HELIX       715    718       {ECO:0000244|PDB:3PDY}.
FT   HELIX       721    778       {ECO:0000244|PDB:3PDY}.
FT   HELIX       788    821       {ECO:0000244|PDB:3PDY}.
FT   HELIX       827    854       {ECO:0000244|PDB:3PDY}.
FT   HELIX       893    900       {ECO:0000244|PDB:3PE0}.
FT   HELIX       904    925       {ECO:0000244|PDB:3PE0}.
FT   HELIX       932    934       {ECO:0000244|PDB:3PE0}.
FT   STRAND      944    948       {ECO:0000244|PDB:3PE0}.
FT   STRAND      964    970       {ECO:0000244|PDB:3PE0}.
FT   STRAND      975    979       {ECO:0000244|PDB:3PE0}.
FT   STRAND      985    989       {ECO:0000244|PDB:3PE0}.
FT   HELIX       990    992       {ECO:0000244|PDB:3PE0}.
FT   HELIX      1000   1024       {ECO:0000244|PDB:3PE0}.
FT   HELIX      1493   1527       {ECO:0000244|PDB:4GDO}.
SQ   SEQUENCE   4684 AA;  531791 MW;  04772E4F70A304C8 CRC64;
     MVAGMLMPRD QLRAIYEVLF REGVMVAKKD RRPRSLHPHV PGVTNLQVMR AMASLRARGL
     VRETFAWCHF YWYLTNEGIA HLRQYLHLPP EIVPASLQRV RRPVAMVMPA RRTPHVQAVQ
     GPLGSPPKRG PLPTEEQRVY RRKELEEVSP ETPVVPATTQ RTLARPGPEP APATDERDRV
     QKKTFTKWVN KHLIKAQRHI SDLYEDLRDG HNLISLLEVL SGDSLPREKG RMRFHKLQNV
     QIALDYLRHR QVKLVNIRND DIADGNPKLT LGLIWTIILH FQISDIQVSG QSEDMTAKEK
     LLLWSQRMVE GYQGLRCDNF TSSWRDGRLF NAIIHRHKPL LIDMNKVYRQ TNLENLDQAF
     SVAERDLGVT RLLDPEDVDV PQPDEKSIIT YVSSLYDAMP RVPDVQDGVR ANELQLRWQE
     YRELVLLLLQ WMRHHTAAFE ERRFPSSFEE IEILWSQFLK FKEMELPAKE ADKNRSKGIY
     QSLEGAVQAG QLKVPPGYHP LDVEKEWGKL HVAILEREKQ LRSEFERLEC LQRIVTKLQM
     EAGLCEEQLN QADALLQSDV RLLAAGKVPQ RAGEVERDLD KADSMIRLLF NDVQTLKDGR
     HPQGEQMYRR VYRLHERLVA IRTEYNLRLK AGVAAPATQV AQVTLQSVQR RPELEDSTLR
     YLQDLLAWVE ENQHRVDGAE WGVDLPSVEA QLGSHRGLHQ SIEEFRAKIE RARSDEGQLS
     PATRGAYRDC LGRLDLQYAK LLNSSKARLR SLESLHSFVA AATKELMWLN EKEEEEVGFD
     WSDRNTNMTA KKESYSALMR ELELKEKKIK ELQNAGDRLL REDHPARPTV ESFQAALQTQ
     WSWMLQLCCC IEAHLKENAA YFQFFSDVRE AEGQLQKLQE ALRRKYSCDR SATVTRLEDL
     LQDAQDEKEQ LNEYKGHLSG LAKRAKAVVQ LKPRHPAHPM RGRLPLLAVC DYKQVEVTVH
     KGDECQLVGP AQPSHWKVLS SSGSEAAVPS VCFLVPPPNQ EAQEAVTRLE AQHQALVTLW
     HQLHVDMKSL LAWQSLRRDV QLIRSWSLAT FRTLKPEEQR QALHSLELHY QAFLRDSQDA
     GGFGPEDRLM AEREYGSCSH HYQQLLQSLE QGAQEESRCQ RCISELKDIR LQLEACETRT
     VHRLRLPLDK EPARECAQRI AEQQKAQAEV EGLGKGVARL SAEAEKVLAL PEPSPAAPTL
     RSELELTLGK LEQVRSLSAI YLEKLKTISL VIRGTQGAEE VLRAHEEQLK EAQAVPATLP
     ELEATKASLK KLRAQAEAQQ PTFDALRDEL RGAQEVGERL QQRHGERDVE VERWRERVAQ
     LLERWQAVLA QTDVRQRELE QLGRQLRYYR ESADPLGAWL QDARRRQEQI QAMPLADSQA
     VREQLRQEQA LLEEIERHGE KVEECQRFAK QYINAIKDYE LQLVTYKAQL EPVASPAKKP
     KVQSGSESVI QEYVDLRTHY SELTTLTSQY IKFISETLRR MEEEERLAEQ QRAEERERLA
     EVEAALEKQR QLAEAHAQAK AQAEREAKEL QQRMQEEVVR REEAAVDAQQ QKRSIQEELQ
     QLRQSSEAEI QAKARQAEAA ERSRLRIEEE IRVVRLQLEA TERQRGGAEG ELQALRARAE
     EAEAQKRQAQ EEAERLRRQV QDESQRKRQA EVELASRVKA EAEAAREKQR ALQALEELRL
     QAEEAERRLR QAEVERARQV QVALETAQRS AEAELQSKRA SFAEKTAQLE RSLQEEHVAV
     AQLREEAERR AQQQAEAERA REEAERELER WQLKANEALR LRLQAEEVAQ QKSLAQAEAE
     KQKEEAEREA RRRGKAEEQA VRQRELAEQE LEKQRQLAEG TAQQRLAAEQ ELIRLRAETE
     QGEQQRQLLE EELARLQREA AAATQKRQEL EAELAKVRAE MEVLLASKAR AEEESRSTSE
     KSKQRLEAEA GRFRELAEEA ARLRALAEEA KRQRQLAEED AARQRAEAER VLAEKLAAIG
     EATRLKTEAE IALKEKEAEN ERLRRLAEDE AFQRRRLEEQ AAQHKADIEE RLAQLRKASD
     SELERQKGLV EDTLRQRRQV EEEILALKAS FEKAAAGKAE LELELGRIRS NAEDTLRSKE
     QAELEAARQR QLAAEEERRR REAEERVQKS LAAEEEAARQ RKAALEEVER LKAKVEEARR
     LRERAEQESA RQLQLAQEAA QKRLQAEEKA HAFAVQQKEQ ELQQTLQQEQ SVLDQLRGEA
     EAARRAAEEA EEARVQAERE AAQSRRQVEE AERLKQSAEE QAQARAQAQA AAEKLRKEAE
     QEAARRAQAE QAALRQKQAA DAEMEKHKKF AEQTLRQKAQ VEQELTTLRL QLEETDHQKN
     LLDEELQRLK AEATEAARQR SQVEEELFSV RVQMEELSKL KARIEAENRA LILRDKDNTQ
     RFLQEEAEKM KQVAEEAARL SVAAQEAARL RQLAEEDLAQ QRALAEKMLK EKMQAVQEAT
     RLKAEAELLQ QQKELAQEQA RRLQEDKEQM AQQLAEETQG FQRTLEAERQ RQLEMSAEAE
     RLKLRVAEMS RAQARAEEDA QRFRKQAEEI GEKLHRTELA TQEKVTLVQT LEIQRQQSDH
     DAERLREAIA ELEREKEKLQ QEAKLLQLKS EEMQTVQQEQ LLQETQALQQ SFLSEKDSLL
     QRERFIEQEK AKLEQLFQDE VAKAQQLREE QQRQQQQMEQ ERQRLVASME EARRRQHEAE
     EGVRRKQEEL QQLEQQRRQQ EELLAEENQR LREQLQLLEE QHRAALAHSE EVTASQVAAT
     KTLPNGRDAL DGPAAEAEPE HSFDGLRRKV SAQRLQEAGI LSAEELQRLA QGHTTVDELA
     RREDVRHYLQ GRSSIAGLLL KATNEKLSVY AALQRQLLSP GTALILLEAQ AASGFLLDPV
     RNRRLTVNEA VKEGVVGPEL HHKLLSAERA VTGYKDPYTG QQISLFQAMQ KGLIVREHGI
     RLLEAQIATG GVIDPVHSHR VPVDVAYRRG YFDEEMNRVL ADPSDDTKGF FDPNTHENLT
     YLQLLERCVE DPETGLCLLP LTDKAAKGGE LVYTDSEARD VFEKATVSAP FGKFQGKTVT
     IWEIINSEYF TAEQRRDLLR QFRTGRITVE KIIKIIITVV EEQEQKGRLC FEGLRSLVPA
     AELLESRVID RELYQQLQRG ERSVRDVAEV DTVRRALRGA NVIAGVWLEE AGQKLSIYNA
     LKKDLLPSDM AVALLEAQAG TGHIIDPATS ARLTVDEAVR AGLVGPEFHE KLLSAEKAVT
     GYRDPYTGQS VSLFQALKKG LIPREQGLRL LDAQLSTGGI VDPSKSHRVP LDVACARGCL
     DEETSRALSA PRADAKAYSD PSTGEPATYG ELQQRCRPDQ LTGLSLLPLS EKAARARQEE
     LYSELQARET FEKTPVEVPV GGFKGRTVTV WELISSEYFT AEQRQELLRQ FRTGKVTVEK
     VIKILITIVE EVETLRQERL SFSGLRAPVP ASELLASGVL SRAQFEQLKD GKTTVKDLSE
     LGSVRTLLQG SGCLAGIYLE DTKEKVSIYE AMRRGLLRAT TAALLLEAQA ATGFLVDPVR
     NQRLYVHEAV KAGVVGPELH EQLLSAEKAV TGYRDPYSGS TISLFQAMQK GLVLRQHGIR
     LLEAQIATGG IIDPVHSHRV PVDVAYQRGY FSEEMNRVLA DPSDDTKGFF DPNTHENLTY
     RQLLERCVED PETGLRLLPL KGAEKAEVVE TTQVYTEEET RRAFEETQID IPGGGSHGGS
     TMSLWEVMQS DLIPEEQRAQ LMADFQAGRV TKERMIIIII EIIEKTEIIR QQGLASYDYV
     RRRLTAEDLF EARIISLETY NLLREGTRSL REALEAESAW CYLYGTGSVA GVYLPGSRQT
     LSIYQALKKG LLSAEVARLL LEAQAATGFL LDPVKGERLT VDEAVRKGLV GPELHDRLLS
     AERAVTGYRD PYTEQTISLF QAMKKELIPT EEALRLLDAQ LATGGIVDPR LGFHLPLEVA
     YQRGYLNKDT HDQLSEPSEV RSYVDPSTDE RLSYTQLLRR CRRDDGTGQL LLPLSDARKL
     TFRGLRKQIT MEELVRSQVM DEATALQLRE GLTSIEEVTK NLQKFLEGTS CIAGVFVDAT
     KERLSVYQAM KKGIIRPGTA FELLEAQAAT GYVIDPIKGL KLTVEEAVRM GIVGPEFKDK
     LLSAERAVTG YKDPYSGKLI SLFQAMKKGL ILKDHGIRLL EAQIATGGII DPEESHRLPV
     EVAYKRGLFD EEMNEILTDP SDDTKGFFDP NTEENLTYLQ LMERCITDPQ TGLCLLPLKE
     KKRERKTSSK SSVRKRRVVI VDPETGKEMS VYEAYRKGLI DHQTYLELSE QECEWEEITI
     SSSDGVVKSM IIDRRSGRQY DIDDAIAKNL IDRSALDQYR AGTLSITEFA DMLSGNAGGF
     RSRSSSVGSS SSYPISPAVS RTQLASWSDP TEETGPVAGI LDTETLEKVS ITEAMHRNLV
     DNITGQRLLE AQACTGGIID PSTGERFPVT DAVNKGLVDK IMVDRINLAQ KAFCGFEDPR
     TKTKMSAAQA LKKGWLYYEA GQRFLEVQYL TGGLIEPDTP GRVPLDEALQ RGTVDARTAQ
     KLRDVGAYSK YLTCPKTKLK ISYKDALDRS MVEEGTGLRL LEAAAQSTKG YYSPYSVSGS
     GSTAGSRTGS RTGSRAGSRR GSFDATGSGF SMTFSSSSYS SSGYGRRYAS GSSASLGGPE
     SAVA
//
